GSK completes Corixa acquisition

GlaxoSmithKline (LSE:GSK; GSK) completed its previously announced acquisition of the 92% of CRXA it did not already own for $4.40 per share, or $300 million, in cash (see BioCentury Extra, Friday Ap...